BASEL · Adapted from Hedge et al., Clin Cancer Res, 2016 IPH5401 Anti-C5aR Lirilumab...

Swiss HLG & PLCF Summer Conference 2018

MAY 16, 2018BASEL

FORWARD LOOKING STATEMENT

This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. Please refer to the risk factors outlined from time to time in the Company’s regulatory filings or publications.

This document contains data pertaining to the Company's potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or

implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice. The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Please refer to the Document de Référence filed with the Autorité des Marchés Financiers (“AMF”) on April 25th, 2018, available on the AMF’s website (www.amf-france.org) and on the Company’s website (www.innate-pharma.com). Such documents may not be necessarily up to date.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

INNATE PHARMA – AT A GLANCE

As of December 31, 2017* cash, cash equivalents as well as current and non-current financial assets

•  Headquarters in Marseille

•  >180 employees

•  Differentiated science in IO

•  Broad R&D pipeline

•  4 products in the clinical stage

•  Partnerships with leading IO companies

•  €176.6 million in Cash*

•  Listed on Euronext Paris

THE IMMUNO-ONCOLOGY REVOLUTION CHANGING THE STANDARD OF CARE IN ONCOLOGY

•  Understand the resistance to Immune Checkpoint Inhibitors

•  Increase the fraction of patients sensitive to IO treatments

•  Decrease toxicity •  Identify new targets (cells and

molecules) •  Identify biomarkers

What’s next

LT survival

Proport

ion a

live

Immunotherapy (monotherapy)

Immunotherapy (combination)

Chemotherapy/TKI

Control

Time from treatment

LT survival

?

INNATE PHARMA – STRATEGY SCIENCE DRIVEN ORGANIZATION AND PATIENT CENTRIC COMPANY

Partner with leading IO companies to unlock the value of assets with substantial market potential

Create broad portfolio of first or best-in-class IO agents

Retain more value in house and move toward integrated biotech

Strategic Priorities

INNATE PHARMA – APPROACH SCIENTIFIC EXCELLENCE AROUND 3 KEY PILLARS

NK/T cell checkpoints

(CP)

1

Tumor antigen

(TAg)

2

Tumor microenvironment

(TME)

3

No effective anti-tumor immunity

Anti-tumor immunity suppressed by TME

Sub-optimal or exhausted anti-tumor immunity

Inflamed

Non

infla

med

Adapted from Hedge et al., Clin Cancer Res, 2016

IPH5401Anti-C5aR

LirilumabAnti-KIR2DL1,2,3

IPH53Anti-CD73

IPH4301Anti-MICA/B

NK Bispecific Engagers

Antibody Drug Conjugates

IPH52Anti-CD39

IPH4102Anti-KIR3DL2

MonalizumabAnti-NKG2A

CP TAg TME

INNATE PHARMA – PIPELINE TARGETING DIFFERENT STATUS OF THE IMMUNE RESPONSE

INNATE PHARMA – PIPELINE FOR FIRST-IN-CLASS IMMUNO-ONCOLOGY (IO) ASSETS

IPH52Anti-CD39

Preclinical

IPH53Anti-CD73

IPH4301Anti-MICA/B

LirilumabAnti-KIR2DL1,2,3

Dose finding

MonalizumabAnti-NKG2A

IPH4102Anti-KIR3DL2

Pivotal

IPH5401Anti-C5aR

Signal detection

IPH61SAN-NKCE-1

Drug Discovery

Anti-Siglec-9

SAN-NKCE-2

Other undisclosed targets

MONALIZUMAB, IN COMBINATION WITH CETUXIMAB IN SCCHN PRELIMINARY DATA SUGGEST PROMISING ANTI-TUMOR ACTIVITY

1 One patient with early death from progression before the 1st assessment is not represented in these graphs.

% reduction of target lesion from baseline1

Cohen et al., AACR 2018

Response rate in skin: 60%

Ma

x ch

an

ge (

%)

in

ab

erra

nt

blo

od

cel

l co

un

t

Best Global Response:

Response rate in blood: 65%

Ma

x ch

an

ge (

%)

in

mSW

AT

sco

re

PDSDPRCR

mPFS 329 days (10.8 months)Min-max (28-610) days

mDOR: 302 days (9.9 months)Min-max (64-519) days

IPH4102, IN PATIENTS WITH SEZARY SYNDROME ENCOURAGING SIGNS OF CLINICAL ACTIVITY IN PHASE 1

Bagot et al., EORTC 2017

IPH5401 – COLLABORATION WITH ASTRAZENECA ACCELERATE PROOF-OF-CONCEPT IN NSCLC AND HCC

AstraZeneca/MedImmune Collaboration

Type of collaboration Clinical agreement (access to drug, 50% trial cost sharing)

Tumor type for expansion cohorts NSCLC 2ary resistance (IO pretreated)IO naive HCC

= unmet medical needs

PD1/PDL1 blockers sensitivity Low

Partner drug Durvalumab

Study design Dose escalationCohort expansion

Study start 2H18

INNATE PHARMA – BUSINESS MODEL BALANCING PARTNERED AND PROPRIETARY PROGRAMS

2003-09 2011

2015 2016

R&D Collaboration

Lirilumab

Bispecifics

Monalizumab

2018

Retain more value in-house for partnered drugs and

build portfolio of proprietary assets

Move toward integrated biopharmaceutical company

IPH5401

INNATE PHARMA – ORGANIZATIONAL MODEL SMALL, AGILE AND EMPOWERED CROSS-FUNCTIONAL TEAMS

Product Portfolio Strategy

Innate Pharma

Research Laboratories

CMC & Pharma operations

Clinical Development

Matrix model

Program leadership

Streamlined decision-making process

INNATE PHARMA – LONG TERM CATALYSTS

First Patient InData read out

* Subject to data/governance decision

Potential BLA

IPH5401 + DurvaPh1/2

Mona + DurvaPh2-SCCHN

Mona + Durva + CTPh1/2

2018 Mona + Cetux

SCCHN

Mona + Durva

IPH4102 cohort expansion in SS

IPH5401 + PD1/L1Ph2-3rd indication

IPH4102Pivotal-SS

IPH4102Pivotal-CTCL

Mona potential pivotal program*

2019

Mona + Durva + CTPh1/2

Mona + CetuxMona + Durva

Update

IPH5401 + DurvaPh1

IPH52Ph1

IPH43Ph1/2

IPH4102Ph1/2 ATLL

IPH4102Ph1/2-PTCL

2020

Mona + DurvaPh2-SCCHN

IPH4102Pivotal-SS

IPH5401 + DurvaPh1/2

IPH5401 + PD1/L1Ph2-3rd indication

IPH52 comboPh1/2

IPH5401 potential pivotal

program*

IPH4102Pivotal-ATLL

IPH4102Pivotal-PTCL

2021

Mona potential pivotal program*

IPH4102 SSPotential BLA*

IPH43Ph1

IPH52Ph1

IPH43Ph2/3

2022

MonaPotential BLA*

IPH4102 Pivotal-CTCL

IPH52 potential pivotal program*


2023+

IPH4102Pivotal-ATLL

IPH4102Pivotal-PTCL

IPH4102 CTCL, ATLL, PTCL

Potential BLA*


IPH5401Potential BLA*

IPH52 combination Ph1/2

INNATE PHARMA – FY2017 RESULTS FINANCIAL STRENGTH, ENABLING INVESTMENTS IN FUTURE GROWTH

Op. expenses: €84m

Cash position: €177m

Revenue*: €44m •  Mainly from industrial partnerships

•  Increase in R&D expenses support clinical development of IPH4102 and monalizumab

•  2017 cash burn €54m** •  Strong cash position to invest in development

pipeline

*revenue and other income** including milestone payment of €14m received in January 2017

INNATE PHARMA – TAKE AWAY KEY VALUE CREATION STEPS

World-class science and technology platform

Clinical read-outs ahead for monalizumab and IPH4102 programs

Delivering on IPH5401 with clinical collaborations to accelerate development

Potential to address large unmet medical needs in cancer

Financial strength, enabling room for investment

INNATE PHARMA – OUR AMBITION BUILDING IO LEADERSHIP

Growing pipeline

3 new medicines

by 2025

More partnerships

Disciplined execution

Investor relations

[email protected] �

Markus MetzgerInvestor Relations

[email protected]

Tel: +33 (0)4 30 30 31 85

INNATE PHARMA - FINANCIAL HIGHLIGHTS ROBUST FINANCIAL POSITION

•  Cash, cash equivalents and financial assets* of €176.6m as of December 31, 2017 >  Cash consumption 2017: €54m (vs €43m for 2016); 2017 excludes €13.8m milestone payment from BMS

>  Tax credit for the fiscal year 2016 (€9.1m net) received in July 2017

In thousand euros (IFRS) Dec. 31, 2017 Dec. 31, 2016

Revenue** from collaboration and licensing agreements 32,631 56,159 Government financing for research expenditures 11,402 9,561 Revenue and other income 44,033 65,721 Research and Development expenses (67,000) (48,628) General and Administrative expenses (17,015) (9,522) Operating expenses (84,015) (58,150) Operating income / (loss) (39,983) 7,571 Financial income / (expenses), net (8,034) 5,370 Corporate tax (368) (301) Net loss (48,835) 12,640 Weighted average number of shares outstanding (in thousands) 54,352 53,869

Net income (loss) per share (0.89) (0.23)

Dec. 31, 2017 Dec. 31, 2016Cash, cash equivalents and financial assets* 176,578 230,664Total financial debt 5,864 5,327

*current and non-current

** revenue mainly relates to the co-development and

commercialization agreement with AstraZeneca,

corresponding to the recognition over the period of

the initial payment received in April 2015

SHARE CAPITAL KEY FIGURES AND ANALYST COVERAGE

•  Listed on Euronext, IPO in November 2006

>  Euronext Paris: FR001331421 – IPH

•  Stock liquidity

>  Average daily trading volume >400,000 (YTD)

>  57.6m outstanding shares (61.1m fully diluted)

*Shareholders represented at the Supervisory Board

15.5%

7.7%

2.2%

74.6%

Novo Nordisk A/S*

BPIfrance Participations*

Management

Other/Autre

•  Analyst coverage:

>  Bryan Garnier

>  Citi

>  Gilbert Dupont

>  Goldman Sachs

>  H.C. Wainwright

>  Invest Securities

>  Leerink Partners

>  Oddo Securities

>  Portzamparc

BASEL · Adapted from Hedge et al., Clin Cancer Res, 2016 IPH5401 Anti-C5aR Lirilumab...

Documents

Transcript of BASEL · Adapted from Hedge et al., Clin Cancer Res, 2016 IPH5401 Anti-C5aR Lirilumab...